Harrow Financial Statements
NASDAQ: HROWHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Harrow revenue and earnings
In fiscal 2025, Harrow generated $272.3 million in revenue, up 36.4% from fiscal 2024, its 5th consecutive year of revenue growth. Harrow reported a net loss of $5.1 million, compared with a loss of $17.5 million a year earlier. Gross margin was 75.1% (down from 75.3%) and operating margin 11.2%.
Diluted earnings per share came in at -$0.14. Over the last 5 fiscal years, HROW's revenue has grown at a 41.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Harrow income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 272.30M | 199.61M | 130.19M | 88.59M | 72.48M | 48.87M | 51.16M | 41.37M | 26.77M | 19.94M |
| Revenue growth (YoY) | +36.41% | +53.32% | +46.95% | +22.24% | +48.30% | -4.48% | +23.67% | +54.52% | +34.26% | +105.25% |
| Cost of Revenue | 67.93M | 49.24M | 39.64M | 25.38M | 18.21M | 14.46M | 16.75M | 16.52M | 13.51M | — |
| Gross Profit | 204.37M | 150.37M | 90.55M | 63.21M | 54.26M | 34.41M | 34.42M | 24.85M | 13.27M | 10.11M |
| Operating Expenses | 173.85M | 141.55M | 90.12M | 61.29M | 52.65M | 34.02M | 39.21M | 30.07M | 25.43M | 25.99M |
| Research & Development | 20.94M | 12.23M | 6.65M | 3.05M | 11.08M | 2.41M | 2.08M | 825.00K | 413.00K | 739.00K |
| Selling, General & Admin | 152.91M | 129.06M | 83.09M | 58.24M | 41.31M | 31.25M | 33.09M | 29.24M | 25.02M | 24.95M |
| Operating Income | 30.52M | 8.82M | 431.00K | 1.92M | 1.61M | 385.00K | -4.79M | -5.22M | -12.16M | -15.88M |
| Interest Expense | 24.18M | 22.79M | 21.32M | 7.24M | 5.44M | — | — | — | — | — |
| Other Income (Expense) | -31.88M | -26.14M | -24.14M | -15.93M | -19.49M | -3.80M | 4.68M | 19.84M | -757.00K | -3.32M |
| Pretax Income | -1.37M | -17.32M | -23.71M | -14.01M | -17.87M | -3.42M | -117.00K | 14.63M | -12.92M | -19.20M |
| Income Tax | 3.77M | 161.00K | 701.00K | 75.00K | 133.00K | 4.00K | 8.00K | — | -935.00K | -111.00K |
| Net Income | -5.14M | -17.48M | -24.41M | -14.09M | -18.01M | -3.36M | 168.00K | 14.63M | -11.98M | -19.09M |
| Net Income growth (YoY) | — | — | — | — | — | -2098.21% | -98.85% | — | — | — |
| EPS (Basic) | -0.14 | -0.49 | -0.75 | -0.51 | -0.69 | -0.13 | 0.01 | 0.67 | -0.60 | -1.50 |
| EPS (Diluted) | -0.14 | -0.49 | -0.75 | -0.51 | -0.69 | -0.13 | 0.01 | 0.61 | -0.60 | -1.50 |
| Shares Outstanding (Basic) | 36.76M | 35.65M | 32.62M | 27.46M | 26.76M | 25.90M | 25.32M | 21.92M | 20.03M | 12.74M |
| Shares Outstanding (Diluted) | 36.76M | 35.65M | 32.62M | 27.46M | 26.76M | 25.90M | 26.47M | 23.81M | 20.03M | 12.74M |
| EBITDA | 31.83M | 10.09M | 1.49M | 3.17M | 3.19M | 2.09M | -2.86M | -3.61M | -10.76M | -14.83M |
| Gross Margin | 75.05% | 75.33% | 69.55% | 71.35% | 74.87% | 70.41% | 67.26% | 60.07% | 49.56% | 50.70% |
| Operating Margin | 11.21% | 4.42% | 33.00% | 2.17% | 2.23% | 79.00% | -9.37% | -12.61% | -45.43% | -79.64% |
| Net Margin | -1.89% | -8.76% | -18.75% | -15.90% | -24.85% | -6.87% | 33.00% | 35.35% | -44.76% | -95.71% |
This table shows 10 annual periods of Harrow's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow HROW's reporting calendar. What is a income statement?